The Kuwait-based North Africa Holding Company (NorAH) signed here Sunday an agreement with Saidal Group to set a joint venture for producing anti-cancer drugs. "The project will cost 25 million euros and take 18 to 24 months to start operation," Boumediene Derkaoui CEO of Saidal Group said in statements on the sidelines of the signing ceremony. He added that the project will cut the bill of anti-cancer drugs imports as it will produce 17 kinds all imported from abroad. Saidal Group and NorAH will have 49 percent-stake each of the project and the remaining two percent will be owned by the National Fund for Investment. For his part, CEO of NorAH Emad Anwar Al-Saleh said the agreement boosts Kuwaiti-Algerian economic cooperation and gives impetus to the bilateral relations between the two Arab nations. The signing ceremony was attended by several Algerian ministers and senior officials along with NorAH employees and Kuwait's Ambassador to Algeria Saud Faisal Al-Duwaish.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor